Supplementary Figures S1-S3 from Repurposing Vandetanib plus Everolimus for the Treatment of <i>ACVR1</i>-Mutant Diffuse Intrinsic Pontine Glioma
<p>Supplementary Figures S1-S3</p>
Publications
6 shownFigure 5 from Repurposing Vandetanib plus Everolimus for the Treatment of <i>ACVR1</i>-Mutant Diffuse Intrinsic Pontine Glioma
<p>Clinical experience of combined vandetanib and everolimus in a 7-year-old girl with ACVR1-mutant DIPG (case 1). <b>A,</b> Timeline summarizing the clinical ...
Figure 1 from Repurposing Vandetanib plus Everolimus for the Treatment of <i>ACVR1</i>-Mutant Diffuse Intrinsic Pontine Glioma
<p>Schema for AI-based identification of a repurposed drug combination strategy for <i>ACVR1</i>-mutant DIPG. The BenevolentAI knowledge graph was employed to ...
Figure 4 from Repurposing Vandetanib plus Everolimus for the Treatment of <i>ACVR1</i>-Mutant Diffuse Intrinsic Pontine Glioma
<p>Efficacy of combined vandetanib and everolimus <i>in vivo</i>. <b>A,</b> Tolerability in NOD.SCID mice exposed to daily oral treatment with the ...
Figure 3 from Repurposing Vandetanib plus Everolimus for the Treatment of <i>ACVR1</i>-Mutant Diffuse Intrinsic Pontine Glioma
<p>Synergy of combined vandetanib and everolimus <i>in vitro</i>. <b>A,</b> Cell viability matrix for <i>ACVR1</i><sup>R206H</...
Figure 2 from Repurposing Vandetanib plus Everolimus for the Treatment of <i>ACVR1</i>-Mutant Diffuse Intrinsic Pontine Glioma
<p>Validation of vandetanib as an ACVR1 inhibitor and everolimus as a P-gp inhibitor. <b>A,</b> Kinome selectivity map for vandetanib at 10 μmol/L, with red ci...
Frequent Co-Authors
Researcher Info
- h-index
- 0
- Publications
- 6
- Citations
- 0
External Links
Impact Metrics
h-index
0
h-index: Number of publications with at least h citations each.